GlobeNewswire Inc | Jan 5, 2022 06:30AM EST

January 05, 2022

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders have been accepted by the 17th Congress of the European Crohns and Colitis Organisation (ECCO), February 16-19, 2022, the worlds largest forum for IBD specialists. ECCOs mission is to improve the care of patients with IBD through international guidelines, education, research, and collaboration.

Details of the guided poster sessions are as follows:

Abstract Tofacitinib tissue exposure correlates with endoscopic outcomeTitle:Presenters: Bram Verstockt, MD, PhD and Sverine Vermeire, MD, PhDSessionDate & February 18, 2022, 12:30 to 13:30 CETTime:Location: Poster Exhibition (Hall C) Characterization of cytokine and drug concentrations in serum,Abstract mucosa and faeces during induction treatment ofTitle: moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodiesPresenters: Joep van Oostrom and Geert D'Haens, MD, PhDAbstract EC22-1198Number:SessionDate & February 18, 2022, 12:30 to 13:30 CETTime:Location: Poster Exhibition (Hall C)

Abstracts will be posted on the ECCO website in mid January. Poster presentations will be made available on the Progenity website following the conclusion of the conference.

About Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of womens health, gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenitys vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Investor Contact:Robert UhlManaging Director, ICR Westwickeir@progenity.com (619) 228-5886

Media Contact:Kate Blom-LoweryCG Lifemedia@progenity.com (619) 743-6294